Disc Medicine Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Disc Medicine Inc.
- Former names
- Gemini Therapeutics, Inc. FS Development Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Watertown
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IRON
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001816736
- EIN
- 85-1612845
Board of directors
-
Donald William Nicholson · DirectorSince 2022
-
Georges Gemayel · DirectorSince 2023
-
Jay T. Backstrom · DirectorSince 2022
-
John D. Quisel · Director · Chief Executive OfficerSince 2022
-
Kevin Bitterman · DirectorSince 2022
-
Liam Ratcliffe · DirectorSince 2022
-
Mark Chin · DirectorSince 2022
-
Mona Ashiya · DirectorSince 2022
-
Nadim Ahmed · DirectorSince 2025
-
William Richard White · DirectorSince 2022
Chief executives
John D. Quisel
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.2%
-
98.6%
Board connections
7 of this board's directors also sit on 10 other boards.
- via Mona Ashiya and William Richard White
- via Jay T. Backstrom
- via Liam Ratcliffe
- via Nadim Ahmed
- via John D. Quisel
- via Liam Ratcliffe
- via Jay T. Backstrom
- via Mona Ashiya
- via Georges Gemayel
- via Liam Ratcliffe
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $120,875,054
- 116 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | John D. Quisel Director, Officer (Chief Executive Officer) | Option exercise | +36,000 | $1.01 | $36,360 |
| Sep 11, 2026 | Kevin Bitterman Director | Option exercise | +7,136 | $45.69 | $326,044 |
| Sep 11, 2026 | Kevin Bitterman Director | Option exercise | +10,000 | $38.85 | $388,500 |
| Sep 11, 2026 | Kevin Bitterman Director | Option exercise | +10,000 | $50.86 | $508,600 |
| Sep 11, 2026 | Kevin Bitterman Director | Open-market sale | −27,136 | $70.11 | $1,902,505 |
| Sep 4, 2026 | Kevin Bitterman Director | Open-market sale | −912 | $79.96 | $72,924 |
| Sep 4, 2026 | Kevin Bitterman Director | Open-market sale | −759 | $79.96 | $60,690 |
| Sep 4, 2026 | Kevin Bitterman Director | Open-market sale | −18 | $79.96 | $1,439 |
| Sep 3, 2026 | Kevin Bitterman Director | Open-market sale | −2,810 | $79.98 | $224,744 |
| Sep 3, 2026 | Kevin Bitterman Director | Open-market sale | −2,339 | $79.98 | $187,073 |
| Sep 3, 2026 | Kevin Bitterman Director | Open-market sale | −54 | $79.98 | $4,319 |
| Sep 2, 2026 | Kevin Bitterman Director | Open-market sale | −26,542 | $80.17 | $2,127,872 |
| Sep 2, 2026 | Kevin Bitterman Director | Open-market sale | −22,090 | $80.17 | $1,770,955 |
| Sep 2, 2026 | Kevin Bitterman Director | Open-market sale | −511 | $80.17 | $40,967 |
| Sep 2, 2026 | Kevin Bitterman Director | Open-market sale | −10 | $80.98 | $810 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.